Europe Humanized Mice Model Market By Type (Genetic Humanized Mice Model v/s Cell-Based Humanized Mice Model), By Application, By End-use, By Country, Competition, Forecast & Opportunities, 2028

Europe humanized mice model market is expected to witness significant growth during the forecast period 2024-2028. The increasing prevalence of cancer, along with the rise in the number of research & development activities in pharmaceutical and biotechnology companies, is anticipated to facilitate the growth of the market. Moreover, ongoing developments in biological research due to continuous support & initiatives from the governments as well as private sectors are likely to propel the market’s growth. In addition to this, the growing demand for personalized medicine is expected to contribute further to market growth. Advances in metabolomics, proteomics, and genomics in the region are creating lucrative growth opportunities in the market. There is a rise in the use of humanized mice models in biomedical research, including human hematopoiesis, regenerative medicines, transplantation, autoimmunity, and infectious diseases, which is surging the demand for humanized mice models. Moreover, rising government investments and grants play a key role in strengthening the growth of the market.

Growing demand for Personalised Medicine

Personalized medicine is basically tailored medicines that are developed to target individualized treatment and care based on genetic or epigenetic makeup and other features. The humanized mice model is treated with a large number of drugs or by gene therapies, which help them to find the most suitable treatment. Thus, there is a rise in the use of humanized mice model for therapeutic strategies in precision medicine. The increasing research expenditure due to a surge in research activities is expected to bolster the growth of the market in the upcoming years. For instance, in 2022, Germany had the highest gross expenditure on research and development (GERD) among European countries, which was 143.1 billion U.S. dollars, followed by France at USD 68.5 billion and then the UK at USD 54.9 billion.

Growing Occurrences of Various Diseases

Rising incidences and prevalence of several diseases, such as cancer, immunodeficiency disorders, and rare diseases, are anticipated to facilitate the growth of the Europe humanized mice model market. According to the Global Cancer Observatory, in 2020, there were 47,86,818 new cases, out of which 5,76,337 cases were of breast cancer, 5,54,569 cases were of colorectum, 5,34,496 cases were of the lung, 5,00,827 cases were of the prostate, 2,21,298 cases were of the bladder, and 2,399,291 cases of other cancers. The rising prevalence of these diseases is surging the demand for clinical studies, which in turn, use humanized mice models to study the efficacy and safety of immunotherapy approaches. Therefore, supporting the growth of the market.

Recent Developments

• In 2020, The Jackson Laboratory announced the availability of a hACE2 transgenic mouse model for coronavirus research. The strategic move assisted the organization in expanding its customer base.
• In 2019, Taconic Biosciences launched genetically engineered mice named TRUBIOME.

Market Segmentation

Europe humanized mice model market is segmented into type, application, end-user, company, and region. Based on type, the market can be categorized into genetic humanized mice model and cell-based humanized mice model. Cell-based humanized mice model is further classified into CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models. Based on application, the market is bifurcated into oncology, immunology & infectious diseases, neuroscience, toxicology, and others. Based on end users, the market is divided into pharmaceutical & biotechnology companies, academic & research institutions, and contract research organizations. In terms of countries, the market is divided into Germany, France, United Kingdom, Italy, Spain, Switzerland, Netherlands, Poland, Sweden, and Belgium.

Market Players

Charles River Laboratories, International, Inc., The Jackson Laboratory, Gempharmatech Co Ltd, Taconic Biosciences, Inc., Envigo (Harlan Laboratories, Inc.), Laboratory Corporation of America Holdings, Janvier Labs, Trans Genic, Inc., genOway, and Creative Biolabd are some of the leading companies in the market.

Report Scope:

In this report, Europe humanized mice model market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Europe Humanized Mice Model Market, By Type:

• Genetic Humanized Mice Model
• Cell-Based Humanized Mice Model
• CD34 Humanized Mouse Models
• PBMC Humanized Mouse Models
• BLT Humanized Mouse Models

Europe Humanized Mice Model Market, By Application:

• Oncology
• Immunology & Infectious Diseases
• Neuroscience
• Toxicology
• Others

Europe Humanized Mice Model Market, By End-User:

• Pharmaceutical & Biotechnology Companies
• Academic & Research
• Institutions
• Contract Research Organizations

Europe Humanized Mice Model Market, By Country:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Switzerland
• Netherland
• Poland
• Sweden
• Belgium

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe humanized mice model market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs.


This product will be delivered within 1-3 business days.